A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen
Latest Information Update: 01 Apr 2025
At a glance
- Drugs Lorundrostat (Primary)
- Indications Hypertension; Resistant hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ADVANCE-HTN
- Sponsors Mineralys Therapeutics
- 29 Mar 2025 According to a Mineralys Therapeutics media release, the detailed results from Advance-HTN were presented in a late-breaking session at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) on Saturday, March 29, 2025, at 1:30 p.m. CT.
- 29 Mar 2025 Results presented in a Mineralys Therapeutics media release.
- 10 Mar 2025 According to a Mineralys Therapeutics media release, the company plans to provide additional data at upcoming medical conferences and in peer-reviewed publications.